Verdant Bio Announces Series C Funding Round Led by Horizon Ventures

September 2026 · Secured by Starproof Reputation's press outreach team · 5 min read

Funding announcements all sound the same — unless you give journalists a reason to care beyond the number. For Verdant Bio's Series C, we anchored the story in patient outcomes: trial data showing faster diagnoses, told through one clinician and one family willing to speak on record.

Harbor Wire took the exclusive under embargo; on announcement day, health trades, national business press, and two broadcast hits followed. Instead of a one-day wire post, Verdant Bio owned a full week of conversation about the future of diagnostics.

"Our Series C deserved more than a wire post. Starproof turned it into a week of tier-one coverage our investors still talk about." — Priya Nair, CMO, Verdant Bio

The coverage drove 800+ qualified job applications in the month after the announcement — and a partnership enquiry from a pharmaceutical company that cited the Harbor Wire piece directly.